Johnson & Johnson (JNJ)vsOrganogenesis Holdings Inc (ORGO)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
ORGO
Organogenesis Holdings Inc
$2.35
+2.17%
HEALTHCARE · Cap: $307.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 16980% more annual revenue ($96.36B vs $564.17M). JNJ leads profitability with a 21.8% profit margin vs 6.6%. ORGO trades at a lower P/E of 15.9x. ORGO earns a higher WallStSmart Score of 67/100 (B-).
JNJ
Buy59
out of 100
Grade: C
ORGO
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+80.1%
Fair Value
$18.81
Current Price
$2.35
$16.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Earnings expanding 555.0% YoY
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 78.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while ORGO is a hypergrowth play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.48 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 59/100) and 78.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?